Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment

S. M L Aversa, S. Stragliotto, D. Marino, F. Calabrese, P. Rigotti, F. Marchini, A. Gambino, G. Feltrin, C. Boso, F. Canova, C. Soldà, R. Mazzarotto, P. Burra

Research output: Contribution to journalArticlepeer-review

Abstract

Post-transplant lymphoproliferative disorders (PTLD) is a serious complication after solid organ transplantation. Reduction of immunosuppression (RI) alone is not able to control the disease. We report a prospective analysis of 30 patients with PTLD after heart or kidney transplantation. Only 5 of 30 patients, treated solely with RI, obtained a complete response. Five patients were treated heterogeneously; in the remaining 20, the efficacy and safety of a weekly anthracycline-based chemotherapy were assessed. Sixteen patients obtained a complete remission. One death was related to treatment. With a median follow-up of 36 months, 3-year overall survival was 63.3% and 57% for the entire group and the chemotherapy-treated group, respectively. Moreover, 4 second neoplasms were observed in the chemotherapeutic group. In this study, we demonstrated that most PTLD need other treatment than RI and a weekly regimen is manageable and has a favourable impact on long-term survival.

Original languageEnglish
Pages (from-to)36-46
Number of pages11
JournalActa Haematologica
Volume120
Issue number1
DOIs
Publication statusPublished - Oct 2008

Keywords

  • Post-transplant lymphoproliferative disorders
  • Solid organ transplantation
  • Weekly chemotherapy

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment'. Together they form a unique fingerprint.

Cite this